Pharmacoeconomics of asthma treatment

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 311-318

  Cleland, Jennifer ^a   Thomas, Mike ^a   Price, David ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asthma; Asthma management; Pharmacoeconomics

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; THEOPHYLLINE DERIVATIVE;

ASTHMA; CLINICAL OBSERVATION; CLINICAL STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC EVALUATION; HEALTH INSURANCE; HUMAN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; COSTS AND COST ANALYSIS; HUMANS; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS;

EID: 0037350891     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.311     Document Type: Review

References (61)

1. SEARS MR: Descriptive epidemiology of asthma. Lancet (1997) 350(Suppl. 2):SII1-SII4.
2. National Heart LaBINIoH: International consensus report on diagnosis and management of asthma (GINA). National Heart, Lung and Blood Institute, National Institutes of Health (1992) 92.3091.
3. SEARS MR: Asthma: basic mechanisms and clinical management. In: Epidemiology. Barnes PJ, Rodger IW, Thomson NC (Eds) Academic Press, San Diego, USA (1992).
4. PEARCE N, WEILAND S, KEIL U et al.: Self-reported prevalence of asthma symptoms in children in Australia, England, Germany and New Zealand: an international comparison using the ISAAC protocol. Eur. Respir. J. (1993) 6:1455-1461.
5. STRACHAN DP, BUTLAND BK, ANDERSON HR: Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. Br. Med. J. (1996) 312:1195-1199.
6. SEARS MR, WILLAN A, HERBISON GP et al.: Associations between atopy, hyperresponsiveness and persistence of childhood asthma. Eur. Resp. J. (1997) 10:162S.
7. HALFON N, NEWACHECK PW:Trends in the hospitalization for acute childhood asthma, 1970 - 84. Am. J. Pub. Health (1986) 76:1308-1311.
8. RABE KF, VERMEIRE PA, SORIANO JB, MAIER WC: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. (2000) 16:802-807.
9. KEATING G, MITCHELL EA, JACKSON R, BEAGLEHOLE R, REA H: Trends in sales of drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975 - 81. Br. Med. J. (Clin. Res. Edn) (1984) 289:348-351.
10. KLAUKKA T, PEURA S, MARTIKAINEN J: Why has the utilization of antiasthmatics increased in Finland? J. Clin. Epidemiol. (1991) 44:859-863.
11. BURNEY PGJ, CHINN S, LUCZYNSKA C et al.: Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Survery (ECRHS). Eur. Resp. J. (1996) 9:687-695.
12. RICKARD KA, STEMPEL DA. Asthma survey demonstrates that the goals of the NHLBI have not been accomplished. J. Allergy Clin. Immunol. (1999) 103:S171.
13. PRICE DB, RYAN D, PEARCE L, BRIDE F: The AIR study: asthma in real life. Asthma J. (1999) 4:74-78.
14. STRACHAN DP: Defining unmet need. Asthma J. (2000) 5:137-140.
15. ADAMS RJ, SMITH BJ, RUFFIN RE: Factors associated with hospital admissions and repeat emergency department visits for adults with asthma. Thorax (2000) 55:566-573.
16. VAN GANSE E, LAFOREST L, PIETRI G et al.: Persistent asthma: disease control, resource utilisation and direct costs. Eur. Respir. J. (2002) 20:260-267.
17. LEGORRETA AP, LEUNG KM, BERKBIGLER D, EVANS R, LIU X: Outcomes of a population-based asthma management program: quality of life, absenteeism, and utilization. Ann. Allergy Asthma Immunol. (2000) 85:28-34.
18. MARKHAM A, ADKINS JC: Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics (2000) 18:591-608.
19. UNGAR WJ, COYTE PC, CHAPMAN KR, MACKEIGAN L: The patient level cost of asthma in adults in South Central Ontario. Pharmacy Medication Monitoring Program Advisory Board. Can. Respir. J. (1998) 5:463-471.
20. CHEW FT, GOH DY, LEE BW: The economic cost of asthma in Singapore. Aust. N Z. J. Med. (1999) 29:228-233.
21. WEISS KB, SULLIVAN SD, LYTTLE CS: Trends in the cost of illness for asthma in the United States, 1985 - 1994. J. Allergy Clin. Immunol. (2000) 106:493-499.
22. WEISS KB, SULLIVAN SD: The health economics of asthma and rhinitis. I. Assessing the economic impact. J. Allergy Clin. Immunol. (2001) 107:3-8.
23. SZUCS TD, ANDERHUB H, RUTISHAUSER M: The economic burden of asthma: direct and indirect costs in Switzerland. Eur. Respir. J. (1999) 13:281-286.
24. BIRNBAUM HG, BERGER WE, GREENBERG PE et al.: Direct and indirect costs of asthma to an employer. J. Allergy Clin. Immunol. (2002) 109:264-270.
25. SERRA-BATLLES J, PLAZA V, MOREJON E, COMELLA A, BRUGUES J: Costs of asthma according to the degree of severity. Eur. Resp. J. (1998) 12:1322-1326.
26. UNGAR WJ, COYTE PC: Measuring productivity loss days in asthma patients. The Pharmacy Medication Monitoring Program and Advisory Board. Health Econ. (2000) 9:37-46.
27. BLANC PD, CISTERNAS M, SMITH S, YELIN EH: Asthma, employment status, and disability among adults treated by pulmonary and allergy specialists. Chest (1996) 109:688-696.
28. BLANC P: Characterizing the occupational impact of asthma. In: Asthma's impact on society: the social and economic burden. Weiss K, Buist A, Sullivan A (Eds) Marcel Dekker, New York, USA (1999).
29. WEISS KB, GERGEN PJ, HODGSON TA: An economic evaluation of asthma in the United States. N. Engl. J. Med. (1992) 326:862-866.
30. BARNES PJ, JOHNSON B, KLIM JB: The costs of asthma. Eur. Resp. J. (1996) 9:636-642.
31. SMITH NM: The 'Needs of People with Asthma' survey and initial presentation of the data. Asthma. J. (2000) 5:133-136.
32. GALLEFOSS F, BAKKE PS: Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomized, controlled trial. Eur. Resp. J. (2001) 17:206-213.
33. MALONE DC, LAWSON KA, SMITH DH: Asthma: an analysis of high-cost patients. Pharm. Pract. Manag. Q. (2000) 20:12-20.
34. BUXTON MJ: The economics of asthma - an introduction. Eur. Respir. Rev. (1995) 6:105-107.
35. JOSEPH KS, BLAIS L, ERNST P, SUISSA S: Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. Br. Med. J. (1996) 312:79-82.
36. BRYAN S, BUXTON MJ: Economic evaluation of treatments for respiratory disease. Pharmacoeconomics (1992) 2:207-218.
37. BARNES NC, THWAITES RM, PRICE MJ: The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir. Med. (1999) 93:402-407.
38. SULLIVAN S, ELIXHAUSER A, BUIST AS, LUCE BR, EISENBERG J, WEISS KB: National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. Am. J. Respir. Crit. Care Med. (1996) 154:S84-S95.
39. SCULPHER MJ, BUXTON MJ: The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics (1993) 4:345-352.
40. STEMPEL DA: Economic analysis of asthma practices. Am. J. Manag. Care (2000) 6:S930-S936.
41. ELPHICK HE, TAN A, ASHBY D, SMYTH RL: Systematic reviews and lifelong diseases. Br. Med. J. (2002) 325:381-384.
42. MILGROM H, BENDER B, ACKERSON L, BOWRY P, SMITH B, RAND C: Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. (1996) 98:1051-1057.
43. LENNEY W, INNES A, CROMPTON GK: Inappropriate inhaler use: assessment of use and patient preference for seven inhaler devices. Respir. Med. (2000) 98:496-500.
44. LINDGREN D, BLAKE B, LARRSON S: Clinical consequences of inadequate inhalation technique in asthma. Eur. J. Respir. Dis. (1987) 70:93-98.
45. BROCKLEBANK D, WRIGHT J, CATES C: Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Br. Med. J. (2001) 323:896-900.
46. PRICE D, THOMAS M, MITCHELL G, NIZIOL C, FEATHERSTONE R: Improvement of asthma control with a breath actuated pressurized metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurized metred dose inhaler (MDI) or a breath-actuated device. Respir. Med. (2003) 97:12-19.
47. JEFF JA, BUSSE WW, PEARLMAN D et al.: Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise induced bronchoconstriction. New Eng. J. Med. (1998) 339:147-152.
48. PRICE D, HAUGHNEY J, DUERDEN M, NICHOLLS C, MOSELEY C: The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics (2002) 20:653-664.
49. British Thoracic Society NACR: The British guidelines on asthma management: 1995 review and position statement. Thorax (1997) 52:S21.
50. TEETER JG, BLEECKER ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest (1998) 113:272-277.
51. BARNES NC: Outcome measures in asthma. Thorax (2000) 55(Suppl. 1):S70-S74.
52. SUISSA S, ERNST P, BENAYOUN S, BALTZAN M, CAI B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. (2000) 343:332-336.
53. SUISSA S, ERNST P, KEZOUH A: Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax (2002) 57:880-884.
54. OZMINKOWSKI RJ, WANG S, MARDER. WD, AZZOLINI J, SCHUTT D: Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeconomics (2000) 18:253-264.
55. JUNIPER EF, GUYATT GH, COX FM, FERRIE PJ, KING DR: Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur. Resp. J. (1999) 14:32-38.
56. FRENCH DJ, CHRISTIE MJ, SOWDEN AJ: The reproducibility of the Childhood Asthma Questionnaires: measures of quality of life for children with asthma aged 4-16 years. Qual. Life Res. (1994) 3:215-224.
57. GIBSON PG, COUGHLAN J, WILSON AJ et al.: Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst. Rev. (2000): CD001117.
58. LAHDENSUO A, HAAHTELA T, HERRALA J et al.: Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. Br. Med. J. (1998) 316:1138-1139.
59. FITZGERALD JM, TURNER MO: Delivering asthma education to special high risk groups. Patient Educ. Couns. (1997) 32:S77-S86.
60. ADAMS RJ, SMITH BJ, RUFFIN RE: Factors associated with hospital admissions and repeat emergency department visits for adults with asthma. Thorax (2000) 55:566-573.
61. RIMINGTON LD, DAVIES DH, LOWE D, PEARSON MG: Relationship between anxiety, depression, and morbidity in adult asthma patients. Thorax (2001) 56:266-271.